Manmeet Singh Soni Sells 3,587 Shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Stock

Reata Pharmaceuticals, Inc. (NASDAQ:RETA – Get Rating) CFO Manmeet Singh Soni sold 3,587 shares of the firm’s stock in a transaction on Friday, March 3rd. The shares were sold at an average price of $87.97, for a total value of $315,548.39. Following the transaction, the chief financial officer now owns 88,926 shares in the company, valued at $7,822,820.22. The sale was disclosed in a document filed with the SEC, which is available at this link.

Reata Pharmaceuticals Trading Down 2.6 %

RETA opened at $88.51 on Tuesday. Reata Pharmaceuticals, Inc. has a 12 month low of $18.47 and a 12 month high of $95.00. The company has a market cap of $3.25 billion, a PE ratio of -10.31 and a beta of 1.27. The company has a 50 day moving average of $44.03 and a 200 day moving average of $35.61.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Robert W. Baird upped their price objective on shares of Reata Pharmaceuticals from $40.00 to $85.00 and gave the stock a “neutral” rating in a research report on Wednesday, March 1st. Barclays lifted their price target on Reata Pharmaceuticals from $50.00 to $90.00 and gave the stock an “overweight” rating in a report on Wednesday, March 1st. The Goldman Sachs Group upped their price objective on Reata Pharmaceuticals from $115.00 to $117.00 and gave the company a “buy” rating in a research note on Friday, February 24th. Stifel Nicolaus lifted their target price on Reata Pharmaceuticals from $75.00 to $105.00 in a research note on Wednesday, March 1st. Finally, Cantor Fitzgerald increased their price target on shares of Reata Pharmaceuticals from $61.00 to $121.00 and gave the company an “overweight” rating in a research report on Wednesday, March 1st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Reata Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $95.00.

Hedge Funds Weigh In On Reata Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. AXA S.A. purchased a new stake in Reata Pharmaceuticals during the 3rd quarter worth about $317,000. BNP Paribas Arbitrage SA grew its stake in Reata Pharmaceuticals by 43.7% during the second quarter. BNP Paribas Arbitrage SA now owns 81,972 shares of the company’s stock valued at $2,491,000 after acquiring an additional 24,938 shares in the last quarter. Endurant Capital Management LP bought a new stake in Reata Pharmaceuticals during the 3rd quarter worth approximately $612,000. Woodstock Corp boosted its holdings in Reata Pharmaceuticals by 9.0% in the 3rd quarter. Woodstock Corp now owns 14,685 shares of the company’s stock valued at $369,000 after purchasing an additional 1,212 shares during the period. Finally, Sofinnova Investments Inc. grew its position in shares of Reata Pharmaceuticals by 4.4% during the 3rd quarter. Sofinnova Investments Inc. now owns 818,376 shares of the company’s stock valued at $20,566,000 after purchasing an additional 34,525 shares in the last quarter. 76.13% of the stock is owned by institutional investors.

About Reata Pharmaceuticals

(Get Rating)

Reata Pharmaceuticals, Inc is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.